Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356018 · ClinicalTrials.gov registry record
Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:
A clinical trial, sponsored by Orlando Health.
- Completed
- Registry status
- 5
- Enrollment target
NCT00356018: Completed study, sponsored by Orlando Health.
NCT00356018 is a clinical trial that has completed, run by Orlando Health. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00356018 has completed, sponsored by Orlando Health.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.
Interventions
- BEHAVIORAL Compliance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-05 |
What the finished NCT00356018 record still lists
NCT00356018 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Compliance is the first listed.
NCT00356018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00356018 about?
NCT00356018 is a clinical study titled "Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:". To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.
What is the current status of trial NCT00356018?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2006-07. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00356018?
The interventions under investigation include: Compliance (BEHAVIORAL).
Who is sponsoring clinical trial NCT00356018?
This trial is sponsored by Orlando Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia